The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R01 Clinical Trial Optional)
ID: 356079Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356079

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-011.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a grant opportunity titled "The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer," aimed at supporting research that explores the intersection of cancer and HIV stigma among individuals diagnosed with both conditions. The primary objectives include enhancing understanding of how these stigmas affect healthcare access, treatment adherence, and overall well-being, while promoting stigma reduction interventions across various socio-cultural contexts. This funding opportunity has a total budget of $5 million, with individual awards capped at $500,000 per year for a project period of up to five years. Interested applicants can find more information and submit their applications by the deadline of December 11, 2024, with the application opening on November 10, 2024. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-011.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-CA-25-011-Full-Announcement.html
    RFA-CA-25-011.html
    The National Cancer Institute (NCI) is seeking applications for research on the interrelationship of cancer stigma and HIV stigma among HIV-positive individuals diagnosed with cancer. This funding opportunity, titled "The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer," outlines a major goal of enhancing understanding and intervention in this area to improve cancer outcomes. Researchers are encouraged to explore the mechanisms through which these stigmas interact, affecting healthcare access, treatment adherence, and overall well-being of affected individuals. The funding amount totals $5 million to support up to six awards, with a project period of five years and a budget cap of $500,000 per year. Key dates include an application opening on November 10, 2024, with a submission deadline of December 11, 2024. This call promotes a multi-level approach to stigma reduction, urging collaboration across various research communities while ensuring the inclusion of diverse populations and the examination of socio-cultural contexts. Applications must adhere to the overarching objectives and eligibility criteria set forth by the NCI, emphasizing rigorous research designs that address both HIV-related and cancer-related outcomes among the target population.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for The confluence of cancer stigma and HIV stigma in HIV-positive individuals diagnosed with cancer (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at exploring the intersection of cancer stigma and HIV stigma in HIV-positive individuals diagnosed with cancer. This initiative seeks to support pilot and exploratory research that enhances understanding of how these dual stigmas affect cancer outcomes and promotes research in both domestic and international contexts, particularly in regions with a high burden of HIV and cancer. The NIH anticipates funding up to three R21 grants, with a total estimated funding of $1,000,000, and the NOFO is expected to be published in late Summer 2024, with applications due in late Fall 2024. Interested applicants are encouraged to prepare by reviewing the initiative's presentation and will find further details on the application process following the NOFO publication.
    Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at reducing HIV-associated stigma to improve prevention, treatment, and care for individuals living with HIV/AIDS in low- and middle-income countries (LMICs). This initiative invites applications for Research Project Grants (R01) to develop and pilot test interventions that address stigma and its impact on health outcomes, particularly focusing on innovative measurement strategies, support for adolescents, and the effects of stigma on caregivers and the aging population. The program emphasizes collaboration between U.S. and LMIC institutions to enhance research capacity and tackle multiple health-related stigmas, including those associated with comorbidities. Eligible applicants can request funding up to $400,000, with a submission deadline of December 22, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-190.html.
    Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)." This initiative aims to support multilevel and multidisciplinary intervention research focused on improving the quality of life and promoting successful aging among individuals living with HIV, particularly those from racial and ethnic minority groups and lower socioeconomic backgrounds. The funding, which ranges from $5-6 million to support approximately 5-6 awards, will provide a maximum budget of $750,000 annually over five years for projects that address social determinants of health and involve community engagement. Interested applicants can find more details and guidelines on the NIH website, with the application process opening on November 11, 2023, and a submission deadline of December 12, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    Addressing Stigma to End the HIV Epidemic in the U.S.
    Health Resources and Services Administration
    The Health Resources and Services Administration (HRSA) is offering a funding opportunity titled "Addressing Stigma to End the HIV Epidemic in the U.S." aimed at supporting an organization that will implement, train, and evaluate anti-stigma interventions to enhance access to HIV care for underserved populations. The selected recipient will manage approximately 20 demonstration sites, facilitate national training, and develop a robust evaluation framework to assess the impact of these interventions over a four-year performance period, with a total funding amount of $25.25 million. This initiative is crucial for improving health outcomes by reducing stigma within healthcare systems, thereby increasing the availability of high-quality care, treatment, and prevention services for individuals affected by HIV. Interested applicants, including public and private nonprofits, state and local governments, and educational institutions, must submit their proposals by March 18, 2025, with the funded program expected to commence on September 1, 2025. For further inquiries, contact LaQuanta Smalley at SPNS@hrsa.gov.
    Elucidating Mechanisms Associated with HIV Related Co-Morbidities in Populations Experiencing Health Disparities (R01 - Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Elucidating Mechanisms Associated with HIV Related Co-Morbidities in Populations Experiencing Health Disparities." This initiative aims to support research that investigates the underlying mechanisms contributing to health disparities in HIV and aging, particularly focusing on how multiple comorbidities affect health outcomes and quality of life among individuals from marginalized populations. The program emphasizes a multidisciplinary approach and encourages engagement with community stakeholders to enhance the relevance of the research. Approximately $3 million is available for four awards and $1.5 million for two additional awards for fiscal year 2024, with a project duration of up to five years. Interested applicants can find more information and guidelines at the NIH Grants website and should direct inquiries to grantsinfo@nih.gov. The application deadline is set for January 7, 2026.
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity titled "Priority HIV/AIDS Research" under the R01 grant mechanism. This initiative aims to stimulate research that aligns with NIH’s priorities regarding HIV/AIDS, particularly focusing on systemic complications such as metabolic, gastrointestinal, and kidney issues arising from HIV, while encouraging the incorporation of health-impeding social determinants of health into research proposals. The anticipated funding amount is $2 million, with plans to support 3 to 5 awards over five years, and applications are due starting May 7, 2025. Interested applicants can find more information and application guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Co-infection and Cancer (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Co-infection and Cancer (R21 Clinical Trial Not Allowed)" aimed at enhancing research on the mechanisms and epidemiology of co-infections in relation to cancer development. This grant seeks innovative proposals that investigate how co-infections, particularly those involving known oncogenic agents (excluding HIV), may influence carcinogenesis and contribute to cancer disparities among diverse populations. The maximum funding amount available for each application is $275,000 over a two-year period, with applications due by November 16, 2025. Eligible applicants include a wide range of institutions and organizations, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use. This initiative seeks proposals that address critical gaps in understanding and improving health outcomes for individuals living with HIV who also face substance use disorders, requiring detailed research plans and preliminary data from both individual researchers and research teams. NIH plans to allocate approximately $3 million annually for three to five awards over three years, with applications due by January 11, 2025, and a strong emphasis on enhancing diverse perspectives through an inclusion plan. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html.
    HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research initiatives focused on HIV-associated non-communicable diseases (NCDs) at low- and middle-income country (LMIC) institutions through the R21 Clinical Trial Optional grant. This program aims to support locally relevant research that explores the relationship between HIV infection and the development of NCDs, enhance research capacity, and foster collaborative networks among researchers in LMICs and the U.S. The grant provides funding up to $275,000 over a two-year period, with a submission deadline of December 8, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.